Gut microbe boosts a brain-calming molecule — hopeful for MS

Credibility

Interest

Share:2 min read

Key Takeaway

A gut bacterium, Veillonella ratti, changed gut chemicals so mice had less brain inflammation—suggesting gut microbes or their products might help protect against MS-related damage.

What They Found

Researchers gave mice a strain of Veillonella ratti from human baby stool and saw that it changed the mix of gut bacteria along the intestine, like rearranging a crowded bookshelf so only certain books stay out. Mice treated with this bacterium had much less inflammation in their brains and spinal cords, and fewer of a kind of immune cell (CD4 IFN-γ+ T cells) that can drive damage. The treatment also calmed down microglia, which are the brain's immune cells that can act like overactive security guards and harm healthy tissue when they are too active. The bacterium worked by reducing other bacteria that carry a gene called pldA, which normally helps make a fat-like molecule called phosphatidylethanolamine. With those bacteria reduced, levels of a specific phosphatidylethanolamine (called DOPE) went up in the gut, blood, and brain, and giving DOPE directly to mice also lowered brain inflammation.

Who Should Care and Why

People with MS and their caregivers should care because this study links gut bacteria and a specific gut-made molecule to lower brain inflammation, which is central to MS symptoms and progression. Think of the gut like a garden: changing which plants grow (bacteria) can change what nutrients and chemicals get into the rest of the body, and some of those chemicals may calm the brain's inflammation. Neurologists and MS care teams might watch this research as it points to future treatments that work through the gut or by using small molecules instead of current immune-suppressing drugs. Caregivers may find it hopeful because interventions targeting the gut could one day add to lifestyle or diet plans that support treatment. Patients who have gut issues, are interested in diet, or take probiotics should discuss these findings with their doctors, since the study suggests the gut can influence brain inflammation but does not yet provide a ready-made therapy.

Important Considerations

This study was done in mice, not people, so results may not work the same way in humans because our bodies and microbiomes are different. The bacterium used came from infant stool and its safety and effects in people are unknown, so it is not a treatment you should try on your own. While DOPE reduced inflammation in mice, researchers need to test dose, safety, and whether long-term changes help symptoms before recommending anything for MS care.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research Nutrition MS Progression

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Experimental & molecular medicine often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News